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This thesis attempts to analyze a part of the big and complex process of how intellectual 
property ownership and technological innovation influence the performance of firms and 
their revenues. Here I analyze firm's stock market performance as a function of the 
quantity and quality of intellectual property (patents) owned by the firm in the context of 
the three US high-technology sectors, Pharmaceuticals, Semiconductors and Wireless. In 
these sectors value of a firm is predominantly driven by the technologies which firm 
owns. I use citation based indicators and number of claims to measure the quality of 
patents. This research presents empirical evidence for the hypothesis that in high-tech 
sectors, companies which generate better quality intellectual property perform better than 
average on the stock market. I also find that firms which are producing better quality 
technologies (good R&D) invest more in R&D regardless of their market performance. 
Furthermore, though smaller firms get relatively lesser returns on quality and quantity of 
R&D they tend to invest a bigger fraction of their total assets in R&D when they are 
generating high quality patents. Larger firms enjoy the super-additivity effects in terms of 
market performance as the same intellectual property gives better returns for them and 
returns to R&D are relatively more in the pharmaceutical industry than semiconductor or 
wireless industries. 
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Chapter – 1 
Introduction 
 
In this knowledge-based economy of our times, intellectual property rights have become 
important strategic resources for firms in the high-technology industries. A patent right is 
not just a means of protection of knowledge about a new technology or products 
discovered by such firms but it also has the potential to improve the market performance 
of the organization. Firms get a short term legal monopoly power in the market when 
their product is protected by intellectual property laws (usually a patent in this case). 
Therefore, such firms have greater assurance of making larger profits, which in turn 
increases the confidence of investors. Thus the advantage of having good technologies 
protected also gets reflected in stock prices.  
 
1.1 Patents as Value Drivers 
Patents are intangible assets for any company, and researchers studying economics of 
technological change have been working on how patents affect the productivity and 
valuation of the firms or what are the returns to the R&D investments. While returns in 
productivity come slowly distributed over time (Bloom and Van Reenen, 2002), stock 
market returns are almost immediate. Better stock performance reflects the market’s 
(external to the company) belief in the success and increased revenues for the company 
due to which the market decides to invest more in the company. On the other hand, R&D 
investments are internal decisions which occur primarily due to the belief of a company 
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in itself or its research capabilities for pursuing the market opportunities while seeking 
and often leading to subsequent buy in from the market into this decision, which would 
further lead to the growth in revenues of the company. Another factor which influences 
R&D spending is the amount of profits made by the firm in any year. 
 
From our knowledge of stock markets, we can conveniently assume here that the stock 
market absorbs each new piece of information and has intelligence to react to it 
depending upon the importance the market gives to that type of information and other 
factors. Moreover, the market is able to provide this response almost immediately without 
a significant lag in time. Hence company announcements about their further investments 
in R&D or new patents being granted etc, are absorbed fast and generate the intelligent 
market reaction for that piece of information.  
 
In this paper we present our research to find empirical evidence for the hypothesis that in 
high-tech sectors, companies which generate better quality intellectual property perform 
better than average on the stock market. Furthermore, we seek to empirically identify any 
other trends or patterns which may be observable at the industry level in the three 
selected US industry sectors with high innovation and patenting activity.  
 
To interpret and measure the performance of the firm, we use the Tobin’s Q, which is the 
ratio of the market value of a firm's assets (as measured by the market value of its 
outstanding stock and debt) to the replacement cost of the firm's assets. Innovation or 
knowledge stock is the independent variable along with the asset value of the firm. Patent 
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indicators, like patent counts, citation counts, number of claims etc are used to measure 
the knowledge stock or innovative technologies owned by the firm. As it is difficult to 
calculate the replacement cost of firm’s assets, typically replacement cost of the 
intangible assets like intellectual property and brand are not included in the calculation of 
Tobin’s Q. Due to this Q values would tend to be greater than one for the firms which 
have significant amount of these intangible assets. Therefore using Tobin’s Q to measure 
the impact on market value of firm due to these intangible assets is a good approach. 
 
1.2 Research Questions 
This paper attempts to analyze a part of the big and complex process of how 
technological innovation and intellectual property influences the performance of firms 
and their revenues. Here we analyze firm’s stock market performance as a function of the 
quantity and quality of patents owned by it for the three US high-technology sectors, 
where value of a firm is predominantly driven by the technologies which firm owns. 
These industry sectors are semiconductor equipment manufacturing (NAICS 334413), 
wireless and communications equipment manufacturing (NAICS 334220) and 
pharmaceutical and medical drugs manufacturing (NAICS 32541). 
 
Six dimensions used in this research for exploring and measuring the effect of innovative 
activity on market performance are: quantity or number of patents, quality of patents 
measured using patent indicators used commonly by researchers, size of company 
measured by the value of its assets, R&D investments, industry and time. The specific 
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research questions explored in this study in the context of these three industry sectors 
with high levels of innovation activity mentioned above are as follows: 
 
- Do companies with more patents perform better then their competitors?  
- Do companies with better average quality of patents perform better? 
- If such an effect of quality or quantity of patents on market value of firms exists, 
then how does it vary across the three different industry sectors considered here? 
- What are the trends of this phenomenon over time?  
- How does it change with value of assets of the company and what are the 
interaction effects among these dimensions? 
- Do companies which are successful in market or are able to do better in R&D 
subsequently invest more in R&D? 
 
Answers to these questions should give a somewhat clearer picture of how technological 
innovation or intellectual property can impact market performance of firms, in what ways 
and how does this impact vary with increasing firm size, amount of innovative activity 
and quality of innovations. Currently we do not know much about how exactly 
shareholders/ investors value a firm’s intellectual property but in this study we intend to 
determine whether there is an effect due to intellectual intangible assets or not, and if yes 
then we discuss and speculate what could be the possible explanations for the 
observations made. A reasonable guess would be that decision makers in market (buyers 
of stock) or in the company (R&D managers) do not use specific indicators for quality of 
patents which we use in our study. Therefore what we are measuring is probably a proxy 
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for some other information which is readily used by them to support their decision 
making under the surrounding uncertainties. 
 
Further elaborate discussion on these issues will be done later in this paper in the results 
section. The remaining sections of this paper are organized as following - next section is 
the literature review, followed by the section on research design where the model used, 
assumptions made and data used will be described with the methodology of analysis and 
discussion over threats to internal and external validity of this research. After that results 
will be discussed, followed by conclusions, suggestions for future work and policy 
implications. 
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In past two decades, research efforts relating to the use of patent data for market 
valuation of firms has gained significant momentum, providing growing evidence that 
R&D output as an intangible capital has become an important determinant of the market 
value of firms. Patents are a good proxy for R&D output of firms, therefore use of 
number of patents and other patent based indicators to evaluate and measure the R&D 
output of firms has become quite popular amongst researchers. Patent data is published 
by the patent offices, so there is very little chance to manipulate it because patent 
examiners make their decisions objectively.  Moreover, patent data is structured, hence it 
is relatively easy to use for the purpose of analysis than the data on journal articles, 
though language of patent data is relatively more ambiguous than an average journal 
article (Porter, 2005).  
 
2.2 Patent Quality Indicators 
Though patent data is authentic and structured, its weakness is that all patents are not of 
the same quality and hence the same value. Griliches (1981, 1990) presented evidence 
that the distribution of values for the patents is highly skewed and thus concluded that 
patent counts or quantity of patents is not a good indicator of R&D output, rather it 
should be the quality of R&D or patents which determines the value of patents. By then 
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Pakes and Schankerman (1984, 1986) had developed a model to measure the patent 
quality and hence value by the observed renewal decisions for these patents.  
 
Trajtenberg (1990) found correlation between the patent citations and independent 
measures of the social value of innovations. Later Putnam (1996) said that family size of 
a patent is also a good indicator of its value. Citations from other patents started getting 
more acceptance as good indicators for patent value when Thomas (1999) analyzed the 
relationship between patent citations, and renewal decision made by patent owners. He 
observed a significant correlation between these across a number of time periods.  
 
Another similar paper by Harhoff et al (1999) used a survey to obtain the private 
economic value estimates for 964 US and German patents for which German patent 
renewal fees were paid to their full-term expiration in 1995. He noted that the patents 
which were renewed to their full-term were much more heavily cited than the patents 
expiring before the full-term, thus establishing that higher the patent’s economic value, 
the more that patent would be subsequently cited. In other words, citations received from 
other patents are a good indicator of the quality of patents. Then to counter this notion 
Jaffe, Trajtenberg and Fogarty (2000) conducted a survey of patentees and concluded that 
though patent citations can tell us a lot about the quality of innovation, they are a noisy 
measure. In the same year Hall, Jaffe and Trajtenberg (2000) published that citation-
weighted patent stocks are more highly correlated with Tobin’s Q ratio of the firms that 
own those patents than patent counts by themselves. This occurs mainly due to the high 
valuations placed by the market on the firms that hold very highly cited patents. 
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2.3 Citations 
Citation count, though noisy, is a well established indicator of patent quality because only 
a fraction of patents receive any citation ever. It is a well chosen construct to measure 
patent quality and value. One big issue with use of citation count as quality indicator for 
patents is that it is available only later in the life span of a patent. Hence in order to 
identify some early stage quality indicators of patents, the idea of using number of claims 
as an indicator of patent quality was proposed by Tong and Frame (1994). They showed 
that patent counts weighted by number of claims are more highly correlated with R&D 
spending at national level. Lanjouw and Schankerman (1997) showed high worth patents 
are litigated more often, and the number of claims correlate well with the probability of 
litigation for the patent. Later Reitzig (2004) found that number of claims was a highly 
significant indicator for patent value and quality at an early stage in the life of a patent, 
where patent value and quality was measured in terms of number of litigation suits faced 
by the patent. 
 
In 2004, using a composite latent variable Lanjouw and Schankerman (2004) showed that 
family size, backward citations and claims are all significant indicators of patent quality 
for which they used patent renewal information as a proxy. It is posited that patents with 
larger family size, full term renewals, and more litigation suits have these characteristics 
because they are more valuable in the market.  
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Around the same time, Bloom and Van Reenen (2002) considered different options 
possible for a firm regarding the use of its intellectual property and used a real options 
framework to show that patents have an economically and statistically significant effect 
on the firm level productivity. They also showed that the higher market uncertainty 
reduces this impact of new patents on the productivity of the firms because this effect 
appears slowly distributed over time, unlike the market performance which is immediate 
and driven by the market sentiments. 
 
Two citation based indicators “generality” and “originality” were discussed by Hall, Jaffe 
and Trajtenberg (2001) in their description file for NBER patent database. These are used 
for examining the impact linkages with the other innovations or patents.  
 
                                    ∑−=
in
j
iji sGenerality 1                    ……….. equation 2.1 
 
where sij is the percentage of citations received by a patent i that belongs to the patent 
class j, out of ni patent classes. The sum is also called Herfindahl concentration index. A 
higher generality score would mean that the patent was cited by subsequent patents which 
belong to a wide range of fields. Thus generality is a measure of breadth of a patent. 
Similarly originality scores are calculated using the references made by the patent. 
Therefore if a patent references other old patents from a wide range of patent classes then 
the originality score of the patent would be higher. This is also a measure of breadth of 
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the patent. In this paper we have used these two indicators (generality and originality) for 
measuring the quality of innovation of the firms. 
 
In this study we attempt to improve the measure of the knowledge stock or quality of 
innovation (patents) for the publicly listed US firms in pharmaceutical, semiconductors 
and wireless industries during the period 1986-1999. To explore whether we can measure 
the patent quality better we use multiple indicators together - number of patents and their 
citation counts along with number of claims, generality and originality indices.  
 
2.4 Market Value and Patents 
While most of the research work mentioned above deals with exploring and relating how 
patent information can be used to analyze the industries as a whole and to identify 
patterns and trends from the data. Narin, Breitzman and Thomas (2004) have developed 
methods (two US patents) and successfully demonstrated the use of patent information to 
stock portfolio selection for getting better returns on investments.  
 
They used three citation based indicators for assessing the quality of technologies which 
a firm owns. These indicators, introduced previously by Deng, Lev and Narin (1999), 
were the following: Current Impact Index (CII), which measures that relative to all US 
patents in the industry sector, how frequently the company’s patents from previous five 
years are cited by patents issued in the most recent year; Science Linkage (SL), which is 
the average number of references a company’s patents make to scientific papers; 
Technology Cycle Time (TCT) which is the median age of the patents cited by a firm’s 
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patents.  They regressed these indicators, patent counts, patent growth and R&D intensity 
as the independent variables with the Market to Book (MTB) value ratio of firms as the 
dependent variable. MTB is an indicator quite similar to the Tobin’s Q which is used 
most often in research. This highlights the critical importance of use of patent data in 
valuation and investment decision making for R&D, stocks or mergers and acquisitions.  
 
Deng, Lev and Narin (1999) used these indicators to determine the extra effect of 
intangible assets on market value of firm, over and above the effect due to earnings or 
profits of the company. An issue which could be raised in their approach is that current 
profits, which are most often considered a proxy for the firm’s future performance in the 
market, would partially be the return on intangible assets like intellectual property owned 
by the firm. Therefore one would not be able to extract out the full effects of intellectual 
property in analysis. 
 
Beginning with Hausman, Hall and Griliches (1984), until Hall (2006), many researchers 
in economics of innovation have used R&D expenses, R&D intensity (i.e. R&D/Sales 
ratio), R&D/Asset ratio or R&D stocks1 as one of the measures of innovative activity 
inside the firm. For this study also, conducting a regression using Negative Binomial 
distribution would have been a better and more insightful idea if we had used the R&D 
stocks distributed over a time period equal to the expected lag for patent outputs from the 
R&D investments, after which these returns truncate. Citations data with truncation 
would provide a good proxy for the quality of patents in that case. The whole stream of 
                                                 
1 R&D stocks for any firm are calculated using declining balance formula and the past R&D spending 
history of the firm. 
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literature starting from Hausman, Hall and Griliches (1984) uses this approach for 
answering research questions on links between R&D investments, product innovation and 
firm’s market performance. They use Poisson Pseudo Maximum Likelihood Estimator 
(PMLE) estimates treating data as one long cross-section with a fixed effects model. 
However, our research question is different; we assume perfect absorption of information 
by the market and then explore the immediate market response to the information 
releases about new patents granted and R&D investments by the firms.  Moreover we 
intend to find comparative strategic insights into the relationship between innovation and 
market performance across three different US industry sectors considered here. 
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Chapter – 3 
Research Design 
 
The research model in this study attempts to find evidence for two forms of decision 
making about the quality and market potential of technology innovations produced by 
any given firm. These forms are the decision of stock market, and that of the firm’s 
internal R&D investments. We hypothesize that both of these decisions are favorable 
when the quality and market potential of technology innovations are perceived good or 
optimistic. Internal R&D investment decision making symbolizes a firm’s belief in the 
potential of technologies it plans to build and its scientists; whereas stock market’s 
decision in the form of Tobin’s Q represents market’s sentiments about the expected 
growth of the firm at any point of time. We examine how and what information the 
market uses for valuing a company’s prospects. This study is an exploratory study only. 
We approach the issue under consideration in a hierarchical manner for an overview of 
causal relations between the quality and quantity of innovations and these forms of 
decision making without delving to the deepest levels in order to find out the exact 
mechanics involving many other variables, in which we are not interested here. 
 
3.1 Model 
The regression model we use in this study has long been in use by researchers in 
economics of technological change (Hausman, Hall and Griliches, 1984). It is derived 
using the standard Cobb-Douglas production function for the market value of firm in 
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terms of the value of its capital assets and knowledge capital.  This Cobb-Douglas 
function is then transformed to measure the impacts of these independent variables on 
market performance measured in terms of Tobin’s Q ratio.  
 
In our analysis, at first we assume knowledge capital (K) as a function of number of 
patents, ratio of R&D expenses to the capital assets C (R&D/C) and time, and run the 
regression. After that we include the quality aspect also and assume patent quality as a 
Cobb-Douglas function with patent indicators used in this study and time as inputs. We 
then compare the results from both of these assumptions. 
 
            ( ) µηδλβαη TCDRClaimsCiteCiteFPatsK &*= …equation 3.1 
 















 …equation 3.2 
 
We also substitute forward citations by “generality” and domestic references (citations) 
by “originality”, which are the other quality indicators for explaining the breadth of 
innovation thereby allowing for a variation in the regression. We make an assumption for 
the relation between forward citations and generality scores, and between citations and 
originality scores. We verified this assumption by performing a regression, which was a 
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highly significant regression with an F-statistic value = 417.24 for the analysis. The 
following relationship was assumed: 
 
                                       cCiteFBGenerality += *                      …equation 3.3 
 
For the factor A, we make an assumption that it is derived by multiplying a generic 
constant and an industry constant. Therefore we get 
                                           
                                                   ακ=A                                                 …equation 3.4 
 
To account for this industry based contribution to the constant, we add dummy variables 
for different industries in our regressions. If we use the additively separable linear 
specification for firm level market value function, which Griliches (1990) and then later 
others have used in previous research work, then again we get the same final model 
equation for our regression analysis. So though his specification makes a good 
assumption that the marginal shadow value of assets is equalized across firms, but later 
one has to assume that the contribution due to the knowledge capital is relatively very 
small, which we are reluctant to assume for the dataset used here. 
 
Therefore by using this model, we investigate effects of the six different factors identified 
from previous literature on the market performance of a firm which is measured by 
Tobin’s Q ratio. These factors are: quantity or number of patents, quality of patents 
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measured by commonly used patent indicators, size of company measured by the value of 
its assets, R&D investments, industry and time.  
 
We conduct regression analyses on the dataset used here with this model in a hierarchical 
manner, by carrying out regressions using independent variables for six different factors 
mentioned above while testing different assumptions or scenarios. To begin with, we use 
number of patents as the only indicator of knowledge capital and then later we add more 
variables which measure the quality of patents. We also carry out the same analysis using 
categorical variables for company size and patenting activity in order to determine if 
there are some differences in patterns observed. We conduct this analysis with a 
combined dataset built for our regressions by using the independent variables and dummy 
variables for industries together. Thereby we assume the same variance in the error term 
across all observations (homoskedastic). As this is time series data, expecting 
heteroskedasticity is highly probable, so we check whether assuming homoskedasticity 
was correct by running separate regressions for industries, separately for each year and 
also by using dummy variables for all years. This is important because the data used is 
from 1986-1999 and we seek to identify patterns or insights which could be valued even 
now. To delve deeper, one could even use firm level dummies to isolate any firm specific 
effects, which do exist. 
 
Other phenomenon of interest, which we explore in this study, is whether firms which are 
performing better in the market or creating good quality intellectual property, invest more 
in R&D or not. For this we regress R&D as a dependent variable with Tobin’s Q and 
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indicators of quantity and quality of intellectual property. Earlier when we had Tobin’s Q 
as our dependent variable we were analyzing the market’s decision on a firm’s potential 
performance or revenues and how it was influenced by the indicators used in the analysis. 
On the other hand, by using R&D investments as a dependent variable we analyze how 
R&D managers, board members or executives of the firm assess or make decisions 
regarding the firm’s potential revenue streams in the form of new products created by 
their R&D divisions. It is assumed that they take their decisions in the best interest of the 
company based on the potential they see in the technology and their firm’s chances of 
capitalizing that potential. 
 
3.2 Assumptions 
In this analysis we make some assumptions which are discussed below with the reasons 
and logic behind doing so, along with their possible consequences in the analysis: 
 
1. We assume that patents represent the intangible assets, due to which stock market 
values the firm more than its book value. This assumption can be justified by the 
fact that patents are exclusive rights to exclude others from the inventions, hence 
treating them as intangible assets is reasonable. Patents have value in themselves 
even when the option of commercialization has been delayed or not considered by 
the firms which own them. This could also be due to strategic reasons like 
licensing revenues or blocking competitors. The literature has provided support 
for this assumption since the pioneering approach from Griliches (1981) by 
finding empirical evidence for it. 
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2. Next we assume that any patent’s economic value is a good indicator of the 
quality of patent and vice versa. This assumption is also supported by the 
literature because it holds true statistically, but it need not be true always. Good 
inventions can and do fail in market due to many reasons and relatively not so 
novel technologies can also succeed in the market. As we are using a sample 
population large enough, we can expect this assumption to hold true. 
 
3. Another assumption we make is, while considering the contribution of intellectual 
property to the intangible assets of the firms, we do not consider the contribution 
of licensing (both licensing in and out) of technologies. We use only the 
technologies created by in-house R&D. We do so because in this study we are 
interested in the effect of intellectual property ownership alone. Licensing 
activities can have a significant effect on the productivity of the firm and thereby 
on its performance in stock market. We do not have data on licensing or cross-
licensing of patents amongst companies, so in order to concentrate on effects due 
to intellectual property owned by the firms, we assume that the effect of licensing 
activity is same for all the companies, which may not be true and could lead to 
either erroneous results or bad fit. As we analyze only the firms from R&D 
intensive sectors and ones pursuing in-house R&D, hence our assumption should 
not distort the results much.  
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4. Normal distributions have been assumed for the variables used in the regression 
analysis. Measures of most of the factors used here are highly skewed but because 
we use natural logarithms of their values in the analysis, so their distributions can 
be approximated to normal (Cameroon and Trivedi, 1998). We checked this 
assumption for all the variables by plotting a histogram for the log values used in 
the analysis and all the distributions appeared to be near normal, which we 
assume is good enough here. 
 
5. We also use Generality and Originality scores of patents in place of Forward 
Citations and Backward Citations (domestic references) in some regressions to 
see how these indicators for breadth of technology correlate with the market 
performance of firms. For verifying whether the substitution relations assumed by 
us were correct, we regressed these new indicators with the respective citation 
counts and validated them. 
 
6. Effects of any Mergers and Acquisitions activity have been assumed to be 
negligible over the patterns identified in the study. These effects are highly 
significant for any individual company and will definitely lead to some error in 
the results, but we do not have any data on the changes in the company structure 
over time. To verify this assumption we conduct our regression analyses with the 
dummy variables for years in place of using one variable for time and also 
separate regressions for each year. In effect, it means we take an industry level 
snap-shot for each year and then compare those snap-shots. This way, if the 
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general patterns observed in the normal analysis appear in these regressions as 
well, then we can be confident that our assumption is reasonable and empirically 
supported by the data used here. 
 
7. We assume that the effect of historical events like the dotcom boom or any other 
industry or economy specific events can be ignored without getting spurious 
results in terms of patterns identified. Use of dummy variables for time should be 
able to isolate any such effects, and if our overall conclusions do not change then 
this assumption holds true. 
 
8. It is assumed that each innovation which results in improved performance, better 
productivity or a new product is being patented. Thereby we ignore the effects of 
trade secrets and business methods. Business method patents came into the picture 
in late 1990s, but even before that innovative business methods were valuable to 
firms. This will lead to an increase in error like the other assumptions but we do 
not have any data on these forms of intellectual properties for companies. 
 
9. We do not consider the effects of labor or human capital in the performance of 
companies because we do not have data on that. Again the assumption is that the 
effect of labor is independent and will not change our conclusions though it will 
decrease our R2 of the analysis. 
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10. Assuming a common model for all the firms in all industries is an obvious 
oversimplification, but we suppose analyzing these three R&D intensive industry 
sectors (Semiconductors, Pharmaceuticals and Wireless) only should control for 
that. To investigate inter-industry differences in our analysis, we use dummy 
variables for the semiconductors and wireless industries, treating pharmaceutical 
as our base sector.  
 
11. Though log values of the variables have been used for analysis on the basis of the 
model assumed but not all non-linear relations in the data could be accounted for 
here. We assume that it will not lead to much change in the significance levels of 
the variables in the results of analysis though standard error will increase due to 
this leading to a lower R2. 
 
12. In our analysis, we do not account for the temporal correlations between the 
patenting activity, patent quality and R&D expenses across different years. Firms 
which invest more in R&D or the ones which have very large patent portfolios 
will tend to get more number of patents and average citations. These effects 
would contribute to and can be determined using the R&D productivity of firms, 
which further leads to better market performance relatively slowly over time.  We 
do not seek to identify these effects as they are not apparent before a significant 
amount of lag time, whereas patent indicators used in this study have an 
immediate effect over our dependent variable of interest, market performance. 
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13. Any firm specific effects on the market performance and R&D innovation have 
been neglected. These would include the organizational culture, leadership, brand 
value etc. It could have been captured by using dummy variables for each firm but 
we are not interested in those effects. 
 
14. We have assumed that Tobin’s Q is a good indicator to measure the firm’s market 
performance for our research because it measures the growth expectations of a 
firm. Moreover, we seek to determine the effect of intellectual property on the 
market performance and thus on the market value of firm. As Tobin’s Q greater 
than one indicates the presence of intangible assets, therefore using it as an 
indicator to measure the effect of intangible assets like intellectual property is a 
valid assumption. 
 
15. We assume that in the selected industry sectors, value of the firm is primarily 
driven the intellectual property owned by the firm. This assumption is in 
congruence with the popular beliefs about these industries, and high patenting 
activity observed in these sectors testifies for this belief. 
 
We seek independent effects due to only the variables we are interested in, so obviously 
our model does not take into account many other different and independent variables 
which could have affected the performance of firms (e.g, locational advantage or 
disadvantage, industry cycles, firm’s life in market, etc.). If data is made available for any 
more such variables then a more rigorous and insightful analysis can be done. 
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3.3 Data 
The dataset used in this study has been made by combining two datasets. Company 
performance data was taken from ATIVO’s Research LLC’s database. We take yearly 
data on Tobin’s Q-ratio values, capital assets and R&D expenses from this database. The 
second database used is the publicly available NBER patent database, which is available 
online from the NBER website. This database was used to get the data on all the patent 
based indicators used in this study.  
 
We first select all the companies which were present in the stock market for five or more 
years during the period 1986-1999 in semiconductor equipment manufacturing (NAICS-
334413, 56 firms), wireless and communications equipment manufacturing (NAICS-
334220, 43 firms) and pharmaceutical and medical drugs manufacturing (NAICS-32541 
69 firms). Then we looked for the patents belonging to each of these companies in the 
NBER patent database. 
 
Company name matching in NBER database is not accurate, firstly because 
company structure data over time is not available in it and secondly, not all patents have 
their assignee/owner names matched. Still the database is of great value because it has 
information on all the patents for the period 1963-1999. It has a numeric variable 
"assignee-id" for each patent, which when searched in another table listed in the database 
gives the name of the company. There can be many assignee-ids allotted to each 
company due to different names of subsidiaries or variations in their company names. 
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Hence, in order to find more matches, a MS Excel macro was made to download the 
patent numbers for each company from USPTO website. We then used these patent 
numbers to extract the other information from the NBER database. After combining both 
set of patents and keeping the unique records only, the number of records in the dataset 
for our use got increased by around 8-10%. Both approaches missed some patents. Patent 
numbers downloaded from USPTO website were less than what one could get from the 
name search in the NBER data. Still 8-10% patents numbers downloaded from USPTO 
had not been matched with the same company in NBER data. All possible name 
variations for the company names were not used while downloading the patent numbers 
from USPTO website using our macro, so these numbers were less than what one can get 
from NBER. Finally, with this two-pronged approach we got 13,831 patent records for 
pharmaceutical companies, 41,828 patent records for semiconductor firms and 13,732 
patent records for the companies in wireless sector. 
 
In the NBER patent database we found many missing entries for some fields, especially 
in the number of claims field. Many times number of claims (which can not be 
zero) was found missing in the NBER data. Most records with missing claims were from 
year 1999 but there was a large number of missing entries for claims in other years too. 
So we substituted these blanks by the mean value of claims for that company's remaining 
patents in that class in that year. This was done assuming that the same patent-attorney 
wrote those patent applications for that company in that year, so the number of claims in 
those patents should have the same mean value. For those records where number of 
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claims entry could not be filled using this method, we relaxed the same year assumption 
at first, and then for the ones still remaining the assumption of same class was relaxed. 
After that only about hundred or less records in each industry category had the number of 
claims missing, so those values were filled in by manually looking up for those patents on 
the USPTO website. 
 
For some records, the entry for number of citations made (domestic references) was also 
missing and an approach similar to claims was used with random manual checking for a 
fraction of these entries to confirm that this process is reasonably correct. There is one 
update available for the NBER data for patents till 2002 at Prof. Bronwyn Hall’s personal 
website at University of California Berkeley. This update does not have values for 
number of claims so we could not use the whole data for analyzing patents till 2002. But 
we used this data to find the updated number of citations received and hence generality 
scores for all the patents in our dataset. 
 
Another issue we faced was that number of citations received and generality scores for 
the patents in later years were obviously not a true value for those. Moreover we used 
only the number of citations received or generality scores for building our dataset, so 
truncating the citation values at a four or five year time period was not possible. To tackle 
this we first plotted the distribution of these values for all patents in the NBER database, 
all patents in our data set and then for the patents for each industry sector in our dataset 
(Figure 1). From a cursory examination of the plot, we could see that the mean values for 
the first four years 1986-89 were roughly the same, and then it started decreasing slowly 
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initially and approached zero rapidly in last few years. We estimated a good fit for this 
distribution (1 – x3 +c, where x is the ratio of time passed from base year to total number 
of years and c is the mean value for the last year).  
 






















Figure 3.1: Mean Generality Score over Time 
 
Citations received and generality scores do not always have a value because not all 
patents receive a citation in their lifespan, hence any substitution to tackle the problem of 
having erroneous values for these fields in later years could be of multiplicative form 
only. Additive substitution would give non-zero values to even those patents which 
probably will never get a citation. So we calculate the mean value for first four years and 
then assume that yearly mean values will tend to reach this value. Thus, we determine a 
yearly multiplying factor for the patents in that industry by dividing the mean of first four 
years by yearly mean of the value calculated from the data. Multiplying 
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generality/citation values in all the records from 1990-99 with the yearly industry 
multiplication factor determined, we get the corrected values to be used further in our 
analysis methodology.  
 
From the plot, we also found that yearly means of generality scores for patents tend to 
reach a uniform distribution given enough time. Another notable observation was that 
yearly means of generality scores in the pharmaceutical industry were significantly less 
than those for the patents from semiconductors industry, and these mean values for 
wireless patents was significantly higher than for semiconductor patents. As generality is 
a measure of breadth of use of technology, obviously wireless application will be more 
generic in nature, followed by semiconductors and then pharmaceutical patents which 
have very narrow applications in only the field of medicine. Hence the pattern in 
generality scores observed is as expected for the industry sectors considered. It shows the 
usefulness of IP protection in these industries and also the relatively higher importance of 
breadth and thus of licensing activities in the wireless and semiconductor sectors. 
 
The next step to be taken was the fixed effects rescaling for the citations, references and 
claims. Mean values for all these fields has been increasing over time due to either the 
sheer propensity to cite or claim more, or other similar reasons. For carrying out fixed 
effects rescaling, we divide each such entry by the yearly mean value for that group or 
patent class. Thus we need not make any assumptions about the underlying reasons due 
to which differences in yearly mean values occur for each of these counts. Though the 
disadvantage here is that by assuming no structured reasons for the difference, we can not 
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distinguish between the real and artificial differences (Hall, Jaffe and Trajtenberg, 2000). 
For claims, the scaling we did was a little more sophisticated, as we used the mean values 
for the same company’s other patents in that class, and relaxing this assumption 
successively as we did in substituting values for the missing claim entries.  
 
Having done all these rescaling and corrections, we calculate the yearly mean values for 
all fields of interest for each company and then in a combined dataset add that year’s 
observation for Tobin’s Q, capital assets and R&D expenses. Next, we create new 
columns for the natural log values of these variables. The next step was to create dummy 
variables for semiconductors and wireless companies with pharmaceutical as the base 
sector, and for each year with 1986 as the base year. After this we created interaction 
terms of interest here and categorical dummy variables according to the asset value or 
company size and patent counts. We also create another datasheet of only those 
observations where Tobin’s Q was greater than one. This is to compare the difference 
between analysis results for all observations and observations with Tobin’s Q value 
greater than one. 
 
3.4 Method 
For this analysis, we perform our regression analyses in the following hierarchical 
manner while noting down results, key observations and differences at each step. To 
begin with, we do the regression with just the dummy variables for industries and the 
other main independent variables in the dataset by considering number of patents as the 
knowledge stock. We do the same analysis for all the observations in the data and then 
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observations with Q-ratio greater than one only. Then in place of the natural log values 
for number of patents and assets, we use the categorical variables created for size and 
patent counts. Next step was to include the indicators for patent quality into the analysis, 
where the natural log of citations and forward citations were used first, and in later 
analyses those were substituted by the originality and generality scores respectively.  
 
Subsequently, we drop the variables which were consistently appearing as totally 
insignificant with high variance inflation factors and include the interaction terms for the 
remaining independent variables. Then we conduct the same analysis separately for 
observations from each industry sector and then separately for the observations from each 
year. We note changes in significance, variance inflation factors of the main independent 
variables, dummy variables and interaction terms for each analysis and the changes in F-
statistic and R2 of the regression for each of these analyses. Cut-off value for variance 
inflation factor used was 25, and for checking significance of variables we consider 1%, 
5% and 10% significance level in our analyses. 
 
Furthermore, we analyze effects of Q-ratio, number of patents and patent quality 
indicators over R&D, in a similar manner as above. This stage-wise approach makes sure 
that the conclusions we draw are consistent. Additionally in order to find the length of lag 
period for returns to R&D in these three sectors we use cross correlation method between 
the time series for Q-ratio and R&D expenses. The cross correlation analysis was done 
individually for only those companies for which data for all 14 years was available. The 
lag values once determined will be compared with expected values for these industry 
sectors to validate the results. 
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3.5 Threats to Validity 
In order to be able to make suitable and fair measurements for drawing right conclusions 
we need to consider the four threats to validity, proposed by Cook and Campbell (1979) 
and discussed by Porter (2005) in perspective of technical data.  These four general 
concerns are following: 
 
– Internal validity 
– Validity of statistical conclusions 
– Construct validity  
– External validity 
 
In the context of our research following is the discussion over each of these threats to 
validity mentioned above: 
 
3.5.1 Internal Validity 
This is to check whether we are able to distinguish if the analysis performed has made 
any real difference by bringing out correct conclusions or we interpret incorrectly 
because the data itself had some sort of bias in it, which mislead the conclusions derived 
from the analyses. 
 
Hence in order to establish internal validity of the research design we have to explore 
whether the data used is a correct measure of what we want to measure and there are no 
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distortions, events or other reasons due to which data may be potentially biased. As we 
have discussed in the previous section describing the data, though imperfect, the 
indicators used here for measuring innovation are the best available right now according 
to the popular school of thought in the literature on economics of innovation or 
technological change. Apart from that, we have taken full care in replacing missing 
values in a careful manner that does not distort the overall distributions and patterns in 
data. The only issue here is that by doing so we tend to decrease the error terms because 
we favor the averages. This may increase our R2 for different analyses a little but as we 
do not use R2 as the main criteria for selection or rejection of variables, or deriving the 
conclusions, rather we just report it, so it should not affect our conclusions. 
 
Secondly, in order to take care of any historical events or industry specific reasons which 
may have altered the patterns and trends in data, we also perform our analysis with 
dummy variables for different industry sectors and different years. Additionally, we split 
the data year-wise and industry-wise, and conduct separate regressions on these sub-sets 
of data. A third factor which we have ignored is if there are some company specific 
reasons for difference, like patenting behavior etc. We do not use separate dummy 
variables for each company to isolate such effects but we create categorical dummy 
variables according to firm-size and the extent of patenting activity. This should take care 
of such issues to a reasonable extent. 
 
The fourth aspect to be considered here is the real probability distributions of these 
variables. Patent data is count data, which by nature follows Poisson distribution, or more 
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precisely it belongs to the standard generalized form of Poisson, Negative Binomial 
distribution. Thus, an Ordinary Least Squares (OLS) estimator is clearly inappropriate for 
the underlying distribution of patent data, because it specifies a conditional mean 
function which may take negative values and a variance function which is 
homoskedastic, so Cameroon and Trivedi (1998) suggest that OLS with log 
transformation of the dependent variables should be used to transform this skewed 
distribution into a normal distribution. That way one can use OLS with patent data; hence 
our log transformation for the model serves this purpose also, along with linearizing the 
regression model used. 
 
3.5.2 Validity of Statistical Conclusions 
This issue involves validation of our results to assure they are statistically significant and 
are not merely chance observations. Normally this validation is done over two 
dimensions - sample size and reliability of measurements. Sample size is not relevant 
here as we use a population and not a random sample for our analysis, and we seek to 
understand the patterns and relations in this population.  We also conduct and prefer the 
combined analysis with dummy variables for industries and interaction terms in this study 
because it assumes the same error distributions all throughout thereby reducing chances 
or erroneous conclusions.  
 
Additionally to increase the robustness of results, we conduct our analysis in a 
hierarchical manner and consider only consistent results as conclusions and report the 
other results. Our use of a commercial database for financial data of firms and patent data 
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(which is structured and reviewed by the USPTO before granting patents) from NBER to 
construct the dataset used in the study enhances the reliability of measurements by 
decreasing noise. 
 
3.5.3 Construct Validity 
This section deals with assuring that the constructs and causal relationships used for 
making the model are proper and there are no omitted variable biases present. We build 
our model based on a popular school of thought from the literature in the field of 
economics of innovation. Hence the constructs and causal relationships used to derive 
this model are well in agreement with the theory on this topic. Furthermore, our use of 
industry specific data may isolate some industry specific local patterns in the data. 
 
3.5.4 External Validity 
In this section we discuss whether the conclusions derived from this study can be 
generalized. We conduct a hierarchical analysis; carrying out the whole analysis 
combined and then in parts, and finally with the use of dummy variables and interaction 
terms to isolate the local patterns and trends (industry or year-wise) from the global 
patterns in the data. Hence, though our data is old (1986-1999), we can generalize our 
main conclusions (global patterns) which appear consistent in analyses and are in 
accordance with theory, for these three industry sectors with high patenting propensity or 
any other similar sectors like biotechnology, chemicals and nanotechnology in the US. 
Any industry specific or time dependent conclusions can not be generalized. 
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 For firms outside US, due to the different patenting systems, generalizing the 
conclusions about the extent of correlation between the patent quality indicators with the 
firm performance could be misleading. However, the generic patterns and causal 
relationships should remain similar reflecting the positive impact of intellectual property 
on firm performance. Hence generalizing these results should not lead to misleading 
conclusions in the context of other countries. 
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Chapter – 4  
Results and Discussion 
 
Results of this study are interesting and align well with the findings of previous research 
work in this field. As mentioned earlier, we attempt to track and measure the changes in 
performance of firms with respect to changes in six basic variables namely: quantity or 
number of patents, quality of patents measured using patent indicators used commonly by 
researchers, size of company measured by the value of its assets, R&D investments, 
industry and time. Following is the table describing the variables used in our research: 
 
Table 4.1: Description of Variables 
Variable Used Description 
LnQ This represents the logarithm of yearly mean of Tobin’s Q of a firm 
LnAsset 
Logarithm of estimated value of Capital Assets of a firm for the 
year 
LnPatents 
Logarithm of number of patents granted to the firm in any given 
year 
LnCiteF 
Logarithm of the corrected average number of forward citations 
received by the patents of a firm in a particular year 
LnCite 
Logarithm of the corrected average number of citations made by the 
patents of a firm in a particular year 
 
LnClaims 
Logarithm of the corrected average number of claims made by the 
patents of a firm in a particular year 
Generality 
Corrected average generality score for all the patents of a firm in a 
particular year 
Originality 
Corrected average originality score for all the patents of a firm in a 
particular year 
LnT 
Logarithm of time passed starting from the base year, T = 
1,2,3,...,14 for 1986-99. 
Sdummy 
Dummy variable for firms belonging to the semiconductor 
manufacturing industry 
Wdummy 
Dummy variable for firms belonging to the wireless manufacturing 
industry 





























    (0.059) 
0.785 





    (0.002) 
-0.196 
    (0.000) 
-0.153 





    (0.016) 
-0.033 
    (0.328) 
0.101 
    (0.003) 
-0.178 





    (0.479) 
0.015 
    (0.665) 
0.049 
    (0.143) 
0.70 
    (0.038) 
-0.044 





    (0.088) 
-0.105 
    (0.002) 
0.011 
    (0.747) 
0.119 
    (0.000) 
0.183 
    (0.000) 
0.158 





    (0.087) 
-0.080 
    (0.017) 
0.054 
    (0.105) 
0.011 
    (0.734) 
0.602 
    (0.000) 
0.162 
    (0.000) 
0.215 





    (0.578) 
-0.093 
    (0.006) 
-0.051 
    (0.128) 
0.084 
    (0.012) 
0.013 
    (0.688) 
0.601 
    (0.000) 
0.115 
    (0.001) 
0.206 





    (0.404) 
0.117 
    (0.000) 
0.060 
    (0.075) 
0.398 
    (0.000) 
-0.468 
    (0.000) 
0.271 
    (0.000) 
-0.003 
    (0.932) 
-.164 
    (0.000) 
0.128 
    (0.000) 
 
( )Values in parentheses are the p-values from significance test of corresponding correlations
 
4.1 Preliminary Analysis 
We began our analysis with calculating the correlation matrix (presented in Table 4.2) for 
the variables used in our analysis. A first look at the correlation matrix suggests that we 
can expect to get the variables representing assets, patent counts, R&D, forward citations 
to appear significant in our regression analyses. Also, we can expect all patent indicators 
to correlate with R&D/Assets at a high degree of significance in our regressions with 
R&D/Assets as dependent variable. Next we conduct our first preliminary regression, 
with number of patents as the measure of knowledge stock or innovative activity inside 
the firms. Following are the results of this preliminary analysis (Table 4.3): 
 
Table 4.3: Coefficients for the Top-level Combined Regression 
Predictor Coef SE Coef T P VIF 
Constant 1.09289 0.08198 13.33 0.000  
LnAsset -0.08432 0.01265 -6.66 0.000 2.9 
LnPatents 0.07427 0.01606 4.62 0.000 2.7 
Sdummy -0.30262 0.04153 -7.29 0.000 1.3 
Wdummy -0.36244 0.05428 -6.68 0.000 1.3 
LnT 0.09217 0.02733 3.37 0.001 1.4 




As we can notice, “p” values and Variance inflation factors (VIF)2 for all the coefficients 
except R&D/Assets ratio are very low, showing that all these variables are highly 
significant and have independent effects over the performance of the company. Though 
the correlation analysis suggested so, R&D/Assets do not appear significant in the 
regression. This may have happened because the causal link we are looking for between 
R&D/Assets and Tobin’s Q may be opposite in direction for the immediate time-frame in 
the context of dataset used here. Theoretically firms can not get immediate returns to 
R&D in terms of revenues. and if Q-ratios do not depend on recent R&D expenses, then 
we interpret it as: the market does not react on announcements by firms about which new 
R&D projects they will start or how much money they are investing in their R&D for any 
cutting edge technologies. Rather the market absorbs the information about patenting 
activity as number of patents granted is positively correlated with Tobin’s Q of the firms. 
According to the literature, we can expect the returns to R&D to be distributed over time 
and we discuss it later in this section. For this analysis R2 was low (10.6%), but F-statistic 
value was quite high (17.43), thereby making this regression highly significant. 
 
Following the methodology described earlier, we add the quality aspect of the patents 
granted with the interaction terms. We note that the quality indicators - citations 
(domestic references), originality and claims – turn out to be statistically totally 
insignificant in this analysis along with R&D/Assets. At the same time, the interaction 
terms which were significant in this analysis extracted the significance effect from the 
variables representing assets and number of patents. As expected, VIFs also increased 
                                                 
2 VIF are used to test for multi-collinearity in multiple regression analysis. High values of VIF indicate 
multicollinearity problems in the analysis thereby suggesting that results may be spurious. 
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due to the use of interaction terms, but in terms of inference we come to know that 
interaction effects amongst independent variables exist in our study, hence not just the 
quantity and quality of patents are important but having both of these together enhances 
the value of firm even more, making it a perfect metaphor for “whole is greater than the 
sum of parts”. 
 
Furthermore, these results tell us that bigger companies with more patents are perceived 
as better investment opportunities by the market. Also for large firms, effect of better 
quality of patents is less which probably hints that larger organizations become 
institutions and their priority is to patent every innovation in order to manage R&D well. 
Further insights on this about how it is different for small and big firms will be discussed 
later in the text where results from the categorical analysis will be described.  
 
We also note that the market performance of firms in these sectors is improving over 
time, thus suggesting that market was valuing high-technology companies more during 
1986-99. Another interesting observation here is, forward citations and generality are the 
quality indicators of patents which are determined at a later stage in the life of a patent, 
but they emerge out as highly significant in our analyses. This possibly means that the 
market has intelligence to foresee which technologies will be more successful in the long 
run. As generality depends on the citations received by the patent from the patents which 
are granted later, we can speculate that it indicates later developments on the same 
technology are market driven. If market analysts of market research predict good 
revenues from any stream of technology, more R&D will be carried out in that 
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technology field, hence these initial patents will receive more citations later. Because 
investments in the stock market are driven by such revenue forecasts, these patents and 
the companies owning them are relatively valued more, even at an early stage in the life 
of patent.  
 
4.2 Detailed Results 
Moving ahead following the analysis methodology, we perform regressions for Q-ratio 
greater than one, for categorical variables for capital size and number of patents, separate 
regressions for industries and years and finally repeat these analysis after dropping the 
variables R&D expenses, originality, domestic references (backward citations) which 
were consistently insignificant in the analyses. We note down all the results and 
following is the table (Table 4.4) of our observations which were consistent in all or most 
of the regressions done in this study. 
 
We aimed to explore answers for some specific research questions in this study along 
with any other patterns or trends which can emerge from our analyses of this data.  Our 
findings from this research are following: 
 
– Results of this study indicate that companies with more patents being granted in 
any specific year perform better on the stock market in that year. No difference 
was found in this observation even when categorical variables were used. When 
interaction terms for interaction amongst the variables LnPatents, lnAsset and 
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generality were used, then the significance of LnPatents gets transferred into the 
interaction terms, but that does not change our interpretation. 
 
– Our results show that firms with better average quality of patents consistently 
perform better on the stock market. In our analysis, only one of our patent quality 
indicators, citations received (also its variant generality) came out significant 
(rather highly significant). This is a strong indicator of quality (other strong 
indicators are family size, renewal data, international patent families, litigation 
data) which can be extracted out from patent data and which we have in our 
dataset. Other indicators used are domestic references and number of claims, 
which are not as strong, and were not found significant. But if patent quality 
appears as highly significant in a macro level analysis like this one, then a more 
sophisticated patent data analysis should be able to extract out the significance of 
these variables as well.  
 
– Regarding the question, “if such an effect of quality or quantity of patents on 
market performance of firms exists, then how does it vary across the three 
different industry sectors considered?” Our answer is: Dummy variables for 
industry sectors were found highly significant consistently in all analyses 
conducted. The coefficients for the variables were negative. Therefore we can say 
that semiconductor and wireless equipment manufacturing industries give lesser 
returns on intellectual property than the pharmaceutical industry. Our 
interpretation of this is, firstly semiconductor and wireless industries are more  
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Table 4.4: Combined Table of Observations 
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competitive and second, most products of the companies in these sectors did not 
fall into the category “vital necessities”, if not in the “consumer luxury” segment 
in the period 1986-99. Both of these reasons explain why these sectors gave lesser 
returns on the quantity and quality of intellectual property owned. 
 
– Another observation is that the time variable in our regression was always found 
highly significant with a positive coefficient. This means on average market value 
of high-technology firms in this time period (1986-99) was increasing with time.  
It could be due to two reasons, markets were growing as surplus income of people 
was increasing during this period, and secondly, value of intellectual property was 
growing in general. Though both of these reasons are also quite correlated but it 
would mean that firms started giving more importance to intellectual property in 
their business during this period. 
 
– Along the company size dimension, which is measured by capital assets, we 
found that coefficient for it was consistently highly significant but contrary to our 
expectation it was negative. But in the categorical analysis where we used dummy 
variables for different company sizes, the coefficients for small company sizes 
were coming negative and for large companies they were positive. Our 
interpretation of this is, smaller companies are not the most popular ones on the 
stock market, even when they have a good patent portfolio. Obviously small 
companies are relatively risky investments in market because they normally do 
  44
not have long history, muscle power (capital assets), brand which can make the 
intellectual property more valuable. Additionally, small firms face the risk of 
failure during expansion or scaling up. This is well in line with the common 
notion that value of intellectual property also depends on who owns it, along with 
other variables. Another noteworthy observation is that most often small 
companies have small patent portfolios, and average patent value for larger 
portfolios is more than the average patent value for small portfolios (Reitzig, 2004 
and Pitkethly 1997).  
 
– We also tested for the interaction effects amongst these variables in our analyses. 
Interaction between assets and industry sectors was not consistently significant in 
different analyses, but coefficients were positive, meaning that bigger companies 
are in a relatively advantageous position in the semiconductor or wireless sector 
than pharmaceutical firms. Interaction between patent quality and industry sectors 
was never significant, and between patent counts and industry sectors was 
significant with negative coefficients. This would mean that in semiconductor and 
wireless sectors, each new patent is of relatively lesser value than it is in 
pharmaceutical industry. A reasonable explanation for this is, semiconductor and 
wireless industries are very consumer oriented (demand driven) and fast changing 
(also converging) industries hence more competition will lead to lower margins, 
whereas in the pharmaceutical sector products remain relevant for longer time 
periods and suitable alternatives are rare (supply driven) so patents are expected 
to be more valuable. 
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When we consider the interactions between the variables for time, assets, patent 
counts and quality (forward citations or generality), then results show that with 
time the importance of assets has grown, whereas importance of patent counts and 
quality has decreased over time. These results are significant but variance 
inflation factors for the interaction terms are quite high (35, 59, 44) which means 
a significant amount of multi co-linearity is present when these interaction terms 
are included in the regression analysis; hence it is highly probable that these 
results could be spurious.  
 
Interaction terms amongst assets, patent counts and generality were also tested, 
and results show that interaction between assets and patent counts, and the 
interaction between assets and generality was highly significant, whereas 
interaction between patent counts and generality was significant at 5% level some 
times and 10% level some other times. Coefficient for interaction between assets 
and generality was negative and other coefficients were positive. This would 
mean that for larger firms in any of these sectors, patent quality is relatively not as 
important as for small firms, in order to perform better. Whereas patent counts are 
definitely more important for large firms, alternatively it may also mean that large 
firms and their investors do not give as high a weight to quality of patents as small 
firms or their investors. For the third interaction term between patent counts and 
generality we have a positive coefficient, thereby meaning that better quality 
patents are more valuable in general.  
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– Regressions conducted separately and with year dummy variables did not show 
much variance in terms of results and significance levels of the variables, but 
some of these regressions were not significant by themselves (low F-statistic), 
though number of observations was enough to provide statistically significant 
results. Separate regression for those years for which year-dummies were 
appearing significant had low F-statistic. Regression for some other years also had 
low F value. We speculate that this means our assumption of same variance 
everywhere for error term is right, though we may be missing out on accounting 
for any general or industry specific events or other causes which affected the 
performance of firms in the time period 1986-99. Probably at the cost of goodness 
of fit (here R2) we were able to get good significance level (high F-statistic) for 
our analyses in this study. 
 
– Analysis of all the observations v/s observations with Q > 1 showed that we get 
better fit and improved significance levels when we use data for Q > 1 only, hence 
we decided to do remaining regressions with observations where Q was greater 
than one. An explanation for this would be that we are exploring how intellectual 
property owned by a firm can explain value of its intangible assets, which are 
apparent only for observations with Q > 1. There could be many reasons due to 
which firms do not perform well in the market and we are not using any variables 
which could address that. 
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– As we noticed before, R&D expenses were not at all significant. This means 
market does not give value to the announcements about future R&D direction and 
spending. Literature says that returns to R&D are lagged and distributed over time 
in years after investment. We therefore attempted to determine the length of lag 
time between R&D investments and returns in the form of company performance 
or high Q-ratio. For this we took only those 35 firms for which we had data for all 
fourteen years. We then performed a cross correlation analysis between the time 
series for Q-ratio and R&D expenses to determine the length of lag period 
individually for each of these firms. In this analysis one has to calculate the 
correlation between the two time series vectors by sliding over other (correlation 
of F(t) and G(t+k) where k = {-n,n}). The point where one observes a peak in the 
correlation, that value of “k” is taken as the length of lag period in years.  
  
The lag period could be determined for only 16 firms, for rest of the firms lag 
values determined either did not make any sense (e.g. negative or zero values, 
very high values) or there was no peak observed in the cross-correlation, so we 
dropped such observations. Average and median length of lag period for 
pharmaceutical firms was 7 years (varied between 6-9 years), for semiconductor 
and wireless firms it was 3 years (varied between 2-6 years for wireless firms and 
1-6 years for semiconductor firms). In all observations, years near the peak 
correlation point also showed high cross correlation. Another observation was that 
all pharmaceuticals firms, for which positive reasonable lag were found, were the 
firms with a low or lower-middle level of patenting activity. For firms with high 
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patenting activity (most often the large firms) these values were zero, and for one 
firm it was found to be one year. As not all lag values could be determined, 
external validity of these results is highly questionable. 
 
Values determined for length of lag period for each of these sectors are quite 
reasonable and as expected, but number of companies for which lag could be 
found was low. Hence we can merely speculate but not claim that the values 
determined are a representative for the respective industry sectors. One reason for 
not being able to determine lag length for all firms could be: for this method to 
work “stationarity” (no trend) for the time series is assumed and both the time 
series for Q-ratio and R&D expenses have growing trends, which would make it 
difficult for this method to work. Cross correlation after differencing was tried but 
it did not yield better results.  
 
Another plausible reason for this is, if annual increase of R&D expenditures is 
marginal, as it normally happens, then there is not a strong reason to expect 
lagged effects on returns, or to be able to isolate the effect of R&D on 
performance which most often would be distributed over years. High correlations 
observed for the years near the peak correlation year would support this 
distributed returns explanation. Though the classical assumption is that firms 
invest in R&D considering expected rates of return of their investments, it is quite 
hard to isolate this effect. Other variables may count here, e.g. market conditions, 
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advertising or business processes. Thus zero or no lag length can be interpreted as 
distributed or continuous returns of R&D on performance. 
 
– The other research question we explored was whether firms which perform well 
on stock market or have good R&D outputs (new products and innovations) in 
turn invest more in R&D than the firms which are not performing so well. In other 
words, do firms try to get into a virtuous cycle of innovation driven growth 
leading to more innovation. As we know, better stock performances are the 
reflection of market’s (external to the company) belief in the success and 
increased revenues for the company due to which market decides to invest more 
in the company. On the other hand, R&D investments are the internal decisions 
which occur primarily due to belief of a company in itself or its research 
capabilities for pursuing the market opportunities, leading to subsequent buy in 
from the market into this decision and finally towards the growth in revenues of 
the company. We analyze R&D investments as dependent variable (R&D/Assets 
is the variable used) within the same year with performance of firm (Tobin’s Q) in 
that year and quality and quantity of patents.  
 
Results for this analysis were highly significant (F-statistic = 48) and show that 
R&D/Asset ratio is not related to the performance of firms on stock market in any 
given year. Variable “number of patents granted” in the same year was significant 
in the continuous regression but not in the categorical regression with categories 
for patenting activity and company size. Assets, time, industry dummies, 
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generality and number of claims were found to be highly significant in the both 
regressions. Coefficient for the time variable used was positive showing that over 
the years R&D/Asset ratio has increased on an average for all successful firms 
(Only firms with Q > 1 were taken in analysis here). Coefficient for assets was 
negative, indicating that as firms grow their R&D/assets ratio does not grow as 
fast, though overall R&D expenses are growing.  
 
In the categorical regression this coefficient for small firms was found positive 
and negative for the large firms. This is interesting and a reasonable observation, 
because we consider the R&D/Assets ratio and it should grow faster for firms less 
than a couple of hundred million dollars worth capital assets than it would for 
firms with assets in billions, even though the increase in absolute R&D expenses 
amount may be much more for the larger firms.  
 
Coefficient for industry dummies was found to be negative, which indicates that 
because pharmaceutical industry products are vital for life and the products from 
semiconductors and wireless sectors are consumer products, hence R&D has 
relatively less importance in these sectors than in pharmaceutical sectors. 
Probably advertising, distribution channels, network size and other aspects of 
business are relatively more important in those sectors.  
 
– Another observation was that the coefficients for generality and number of claims 
were both highly significant and positive. This translates into more R&D 
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investments for firms which are already conducting good R&D. Explanation for 
generality’s significance can be that it denotes the market research and market 
feedback or reviews, and that is the reason R&D managers or board members 
pump in more money into further research. For claims, the explanation becomes 
more speculative. It is a weak indicator of quality and no R&D investment 
decision maker would look into the patent applications to see how many claims 
were made in order to decide further investments in that research stream.  
 
Number of domestic references (represented by originality here) is an equally 
good indicator of quality as number of claims, but that was not found significant. 
We therefore speculate that number of claims is indirectly related to or acting as a 
proxy for the performance or assessment of the capabilities of researchers in the 
firm. If we assume that final claims in a patent application are quite similar to 
whatever claims about scope and use of technology that were made in the 
proposals by these researchers while requesting funds, then number of claims in a 
patent can be expected to behave as a proxy for the performance or capabilities of 
the inventors. This would justify more investments in the research to expand on 
the patented technology, because R&D managers can believe the claims inventors 
are making for their future research. It may also suggest that internal R&D 
decision making of firms can not be called fully rational if belief in what 
inventors claim could affect investment decisions. As R&D investment decision 
making is itself a large and growing research area in decision sciences, this 
speculation could be worth exploring further. 
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Finally, in this study we found that in all our regressions adjusted R2 values were quite 
low (between 10-25%). This suggests that the relationships observed are quite noisy, 
thereby reflecting the complexity of stock market valuations which lead to high levels of 
noise in modeling. However our regressions were highly significant with F-statistic 
values greater than 10, which suggests that these causal relationships posited are 
empirically well supported by the dataset used here, and one can rely on these insights.  
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Chapter – 5  
Conclusions, Future Work and Policy Implications 
 
4. 1 Conclusions 
The results of this paper show that the immediate market performance, and thus market 
value of high technology firms with yearly mean of Tobin’s Q-ratio greater than one 
correlates significantly with both quantity and quality of patents granted to the company. 
Furthermore, the market gives better returns to technology innovation for pharmaceutical 
firms than for semiconductor or wireless companies. Additionally, we show that strong 
interaction effects amongst the variables - assets, patent quantity and patent quality exist 
in determining the market value of a firm. Except for the interaction term between assets 
and quality of patents, the coefficients for the interactions were positive, which implies 
super-additivity in effects of intellectual property over market performance because 
combined effects of patent quality and quantity, and firm size and patent counts are more 
than the sum of these effects individually on a firm’s market performance.  This super-
additivity phenomenon puts small firms on a very disadvantageous position relative to the 
large firms. 
 
The other finding was that R&D investments by firms do not depend on the performance 
of these firms in market. But it does depend on the quality of patents which also 
influences the market performance of firms. Therefore both market value and the R&D 
expenses of a firm in any given year get influenced by the quality of patents granted to it 
in that year. The relationship between market performance and R&D investments is not 
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apparent in the same year, but lagged and distributed or continuous returns to R&D on 
market value were observed in a subset of data. Results and the model used in this 
research do not account for all innovation activity happening in the industries and any 
licensing activities taking place amongst firms. 
 
4.2 Future work 
This study provides us with some good and interesting results, which lead to further 
research questions to be explored in depth. Here we present some of these questions 
which are definitely worth further research: 
 
 We use the OLS estimator in this study which involves patent and citations count 
data. This leads to a bad fit in our results though significance levels of the analyses 
and variables were quite high. Hence if the research question demands, one can use 
another regression model which would be more suitable for count data (negative 
binomial distribution based) to increase the fit.  
 
 Companies do not always take up the option of commercialization for each patent 
granted to them. If data can be gathered then exploring the same research questions 
with a real-options based model considering all options over any patent which a 
company has after getting the patent granted, would definitely provide a much better 
understanding of R&D investment decision making within the firms and its impacts 
on the market performance of firms. 
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 As we noticed, dummy variables for semiconductors and wireless industries were 
found negative consistently in all our regressions. This could be well worth the 
research effort to explore and empirically support any explanations for this 
phenomenon.  
 
 Assuming a linear relationship between firm performance and independent variables 
used itself is an assumption which could be verified using an “artificial neural 
networks” based estimator, which could determine the nonlinear relationships. 
 
 We could not determine lag values for all the firms from our dataset but that is a very 
interesting research question worth much more detailed investigation. Using a larger 
and more detailed dataset this could be achieved. 
 
Like any other research, this study also leads to many more questions to be answered 
subsequently in further research. Yet it provides some useful insights into how market 
performance of firms is related to its intellectual property, size, time and industry 
characteristics in any given year.  
 
4.3 Policy Recommendations 
Along with other challenges of growth and expansion, small firms have to also face the 
fact that though intellectual property gives them a lot of advantage, but proportionately it 
gives more advantage to large firms. This provides ample opportunities for the policy 
makers to attempt making the competition fair or leveling the field by putting in place 
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policy initiatives or scaffolding to support smaller firms. Furthermore, policy makers can 
work on ways to decrease different forms of uncertainties associated with the businesses 
in the economy, as it would be helpful to all firms. Another area for policy initiatives 
could be to standardize and mandate the information disclosures about finer details of 
R&D expenses reporting and information about technologies licensed in or out from the 
company, to make the business activities in the industries more transparent for 
competitors and investors. 
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Appendix – I: Description of Data Statistics 
Following are the plots describing the characteristics of the data used in this study in 
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Figure A1.2: Asset Value Distribution of Firm Data Observations 
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Yearwise Distribution of Observations
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Summary for Ln(Patent Counts)
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Summary for LnCiteF (scaled)
 
Figure A1.9: Statistical Summary for Natural Log of Average Number of Citations 
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Figure A1.10: Statistical Summary for Natural Log of Average Number of Claims Made 
by the Firm’s Patents of that Year 
Descriptive Statistics 
Table A1.1: Descriptive Statistics 
Variable Mean SE Mean TrMean StDev Min Q1 Median Q3 Max 
Patent Counts 59.0800 6.7200 25.7700 200.3500 1.0000 2.0000 6.0000 28.5000 2837.0000
LnPatents 2.1592 0.0611 2.0443 1.8241 0.0000 0.6931 1.7918 3.3495 7.9505
Assets 4301.0000 389.0000 2416.0000 11605.0000 2.2200 61.2000 185.0000 2587.0000 120463.0000
LnAssets 5.8604 0.0801 5.8259 2.3889 0.7953 4.1139 5.2224 7.8582 11.6991
Q Ratio 2.7684 0.0806 2.4434 2.4045 1.0020 1.4920 2.1325 3.1873 30.2440
LnQ 0.8302 0.0187 0.7953 0.5569 0.0020 0.4001 0.7573 1.1592 3.4093
R&D Expenses 854.4000 73.4000 469.0000 2190.7000 0.0000 10.2000 46.5000 284.1000 20123.0000
R&D/Asset 0.2417 0.0060 0.2278 0.1777 0.0000 0.1204 0.2157 0.3066 1.0908
Sales 2604.0000 249.0000 1381.0000 7430.0000 0.0000 16.0000 102.0000 1233.0000 87548.0000
CiteF 6.6770 0.3550 5.1680 10.5820 0.0000 1.0000 3.6670 8.0000 135.0000
LnCiteF 0.3764 0.0918 0.5545 2.7394 -6.0000 0.0000 1.2993 2.0794 4.9053
Cite 9.6910 0.3710 8.2070 11.0780 0.0000 4.6970 7.1230 10.9540 137.4000
LnCite 1.9673 0.0254 1.9674 0.7561 -1.3863 1.5751 1.9652 2.3956 4.9229
Claims 1.1348 0.0202 1.0770 0.6013 0.0613 0.8190 1.0070 1.3069 6.2344
LnClaims 0.0081 0.0168 0.0204 0.5017 -2.7917 -0.1996 0.0069 0.2676 1.8301
Generality 0.3334 0.0090 0.3202 0.2690 0.0000 0.0000 0.3362 0.5123 0.9000
Originality 0.3825 0.0064 0.3825 0.1897 0.0000 0.2771 0.3836 0.5000 0.8711
Appendix – II: Results 
Following are the representative set of results from this study which have not been 

















































Normal Probability Plot of the Residuals Residuals Versus the Fitted Values
Histogram of the Residuals Residuals Versus the Order of the Data
Residual Plots for LnQ
 
Figure A2.1: Residual Plots for LnQ as Dependent Variable 
 
 
Results for Regression Analysis with R&D/Asset as a Dependent Variable  
The regression equation determined is: 
RDbyAsset = 0.160 - 0.00666 LnQ + 0.00857 LnPatents - 0.0244 LnAsset 
            + 0.0268 lnclaims-scaled + 0.00226 LnCiteF - 0.0888 sdummy 
            - 0.125 wdummy + 0.130 LnT 
Standard Error = 0.149082   R-Sq = 30.2%   R-Sq(adj) = 29.6% 
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Table A2.1: Analysis of Variance 
Source DF SS MS F-statistic p-value 
Regression 8 8.4785 1.0598 47.68 0 
Residual Error 881 19.5806 0.0222   
Total 889 28.0591    
 
 
Table A2.2: Coefficient Values for Independent Variables 
Predictor Coef SE Coef T P VIF 
Constant 0.15995 0.025 6.4 0  
LnQ -0.006659 0.009478 -0.7 0.483 1.1 
LnPatents 0.008568 0.004675 1.83 0.067 2.9 
LnAsset -0.024366 0.003609 -6.75 0 3 
lnclaims-scaled 0.02681 0.01036 2.59 0.01 1.1 
LnCiteF 0.002258 0.002184 1.03 0.031 1.4 
Sdummy -0.0888 0.01181 -7.52 0 1.3 
Wdummy -0.12502 0.01502 -8.32 0 1.2 

















































Normal Probability Plot of the Residuals Residuals Versus the Fitted Values
Histogram of the Residuals Residuals Versus the Order of the Data
Residual Plots for R&D/Asset
 




















      
Pharma      
 XOMA 7   0.531  Low Yes 
 WYE 7   0.246  Mid Yes 
 RGEN 6   0.416 7   0.401 Low Yes 
 PFE 0   0.902 1   0.742 High  
 NVO 0   0.852 1   0.733 High  
 MRK 0   0.677 1   0.499 High  
 LLY 0   0.640 1   0.530 High  
 JNJ 0   0.861 1   0.747 High  
 IMMU 7   0.307  Low Yes 
 GSK 2   0.628 1   0.591 Mid  
 CYTO 0   0.246 1   0.213 Low  
 BOL 8   0.419 9   0.411 Mid Yes 
 BMY 0   0.620 1   0.567 High  
 AMGN 0   0.281 1   0.200 Mid  
      
Semiconductor     
 ADI 2   0.569 3   0.529 Mid Yes 
 AMD 3   0.337 2   0.327 High Yes 
 CY 4   0.238 5   0.194 Mid Yes 
 ENER 4   0.553 5   0.491 Mid Yes 
 IBM 6   0.622 7   0.583 High  
 IDTI 3   0.299 4   0.283 Mid Yes 
 INTC 0   0.935 1   0.721 High  
 LLTC 0   0.836 1   0.686 Low  
 LSCC 1   0.280 2   0.274 Mid Yes 
 LSI 0   0.512 1   0.478 High  
 MSCC 5   0.668 4   0.578 Low Yes 
 MU 0   0.287 1   0.272 High  
 NSM 2   0.562 1   0.531 High Yes 
 SMSC 10   0.221 11   0.205 Low  
 TXN 0   0.687 1   0.602 High  
 XLNX 0   0.562 1   0.388 Mid  
      
Wireless      
 KYO 5   0.279  6   0.257 Mid Yes 
 MOT 2   0.365 1   0.302 High Yes 
 QCOM 3   0.324 4   0.256 Mid Yes 
 
Though these results are as expected, but they can not be taken as valid for generalization 
to the dataset used in this study and obviously for any other similar dataset. 
